A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 650 participants.
Also called NCT07820930
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 650 participants
- Sponsor
- Registry
-
NCT07820930
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07820930. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation
- Acronym
- ReDEFINE-AF
- Condition
- Atrial Fibrillation (AF)
- Condition
- Persistent Atrial Fibrillation (PersAF)
- Condition
- Paroxysmal Atrial Fibrillation (PAF)
- Intervention (Device)
- FARAFLEX Mapping and Pulsed Field Ablation System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct07820930- Content hash
b8ee4c68589de7d3f9403c3c8f0ce02cb5360085a00578853b15cdd4bbe94f33